The stock of Connect Biopharma Holdings Ltd ADR (CNTB) has seen a 28.80% increase in the past week, with a 27.78% gain in the past month, and a 71.28% flourish in the past quarter. The volatility ratio for the week is 10.79%, and the volatility levels for the past 30 days are at 11.11% for CNTB. The simple moving average for the past 20 days is 29.47% for CNTB’s stock, with a 46.52% simple moving average for the past 200 days.
Is It Worth Investing in Connect Biopharma Holdings Ltd ADR (NASDAQ: CNTB) Right Now?
Additionally, the 36-month beta value for CNTB is -0.71. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNTB is 53.08M and currently, short sellers hold a 0.20% ratio of that float. The average trading volume of CNTB on March 28, 2024 was 132.19K shares.
CNTB) stock’s latest price update
Connect Biopharma Holdings Ltd ADR (NASDAQ: CNTB) has experienced a rise in its stock price by 21.05 compared to its previous closing price of 1.33. However, the company has seen a gain of 28.80% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-19 that SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m. ET. Please see below for additional details about the event and how to request a one-on-one meeting with management.
Analysts’ Opinion of CNTB
Many brokerage firms have already submitted their reports for CNTB stocks, with H.C. Wainwright repeating the rating for CNTB by listing it as a “Buy.” The predicted price for CNTB in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on March 04, 2024 of the current year 2024.
SVB Leerink, on the other hand, stated in their research note that they expect to see CNTB reach a price target of $32. The rating they have provided for CNTB stocks is “Outperform” according to the report published on April 13th, 2021.
CNTB Trading at 33.98% from the 50-Day Moving Average
After a stumble in the market that brought CNTB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.31% of loss for the given period.
Volatility was left at 11.11%, however, over the last 30 days, the volatility rate increased by 10.79%, as shares surge +36.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +56.33% upper at present.
During the last 5 trading sessions, CNTB rose by +28.80%, which changed the moving average for the period of 200-days by +47.71% in comparison to the 20-day moving average, which settled at $1.2650. In addition, Connect Biopharma Holdings Ltd ADR saw 36.44% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CNTB
The total capital return value is set at -0.1. Equity return is now at value -51.10, with -46.09 for asset returns.
Based on Connect Biopharma Holdings Ltd ADR (CNTB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -17.6. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -3925.63.
Currently, EBITDA for the company is -762.07 million with net debt to EBITDA at 6.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.26.
Conclusion
In conclusion, Connect Biopharma Holdings Ltd ADR (CNTB) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
